While the immune reset field is mainly focused on depleting pathogenic B cells, ai3Bio is applying its novel approach to inflammatory T cells. The startup’s initial disease targets are autoimmune disorders of the liver that have few treatment options if any at all.
The post Immunology Startup ai3Bio Aims to Redefine What It Means to Reset the Immune System appeared first on MedCity News.
